Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Desvenlafaxine
Drug ID BADD_D00621
Description Desvenlafaxine (O-desmethylvenlafaxine) the major active metabolite of venlafaxine, is an antidepressant from the serotonin norepinephrine reuptake inhibitor (SNRI) class[Label]. Desvenlafaxine may be used to treat major depressive disorder[Label]. It is formulated as an extended release tablet[Label]. Desvenlafaxine was approved by the FDA in 2008[L6016].
Indications and Usage Desvenlafaxine is indicated for the treatment of major depressive disorder in adults[A6990,A6991,Label].
Marketing Status approved; investigational
ATC Code N06AX23
DrugBank ID DB06700
KEGG ID D07793
MeSH ID D000069468
PubChem ID 125017
TTD Drug ID D0O3FG
NDC Product Code 63304-191; 0054-0401; 0054-0603; 14501-0068; 70436-013; 70771-1311; 68382-469; 0054-0400; 70436-036; 70771-1312; 0591-3660; 71335-1815; 68382-105; 46708-152; 70518-3195; 69766-025; 60687-607; 63304-192; 70771-1661; 68382-741; 72888-144; 46708-153; 53002-1801; 71335-1753; 71335-1975; 72888-143; 63629-7524; 70436-012; 0591-3659; 71335-1700; 0591-4060; 50090-4806
UNII NG99554ANW
Synonyms Desvenlafaxine Succinate | Succinate, Desvenlafaxine | O-desmethylvenlafaxine Succinate Monohydrate | Monohydrate, O-desmethylvenlafaxine Succinate | O desmethylvenlafaxine Succinate Monohydrate | Succinate Monohydrate, O-desmethylvenlafaxine | 2-(1-hydroxycyclohexyl)-2-((4-hydroxyphenyl)ethyl)dimethylammonium 3-carboxypropanoate monohydrate | O-desmethylvenlafaxine Succinate | O desmethylvenlafaxine Succinate | Succinate, O-desmethylvenlafaxine | WY 45,233 | 45,233, WY | WY-45,233 | WY45,233 | WY-45233 | WY45233 | WY 45233 | 45233, WY | Pristiq | Desvenlafaxine | O-desmethylvenlafaxine | O desmethylvenlafaxine | 4-(2-(dimethylamino)-1-(1-hydroxycyclohexyl)ethyl)phenol
Chemical Information
Molecular Formula C16H25NO2
CAS Registry Number 93413-62-8
SMILES CN(C)CC(C1=CC=C(C=C1)O)C2(CCCCC2)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abnormal dreams19.02.03.001; 17.15.02.0010.001783%Not Available
Affective disorder19.04.04.0010.000695%Not Available
Aggression19.05.01.0010.001141%Not Available
Agitation19.06.02.001; 17.02.05.0120.004065%
Alopecia23.02.02.001--
Amenorrhoea21.01.02.001; 05.05.01.0020.000392%
Amnesia17.03.02.001; 19.20.01.0010.001622%
Anaphylactic reaction24.06.03.006; 10.01.07.001--
Anger19.04.02.0010.002692%Not Available
Angioedema22.04.02.008; 23.04.01.001; 10.01.05.009--Not Available
Angle closure glaucoma06.03.01.001--Not Available
Anorgasmia19.08.01.0010.000606%
Anxiety19.06.02.0020.009146%
Apathy19.04.04.0020.000606%Not Available
Arrhythmia02.03.02.0010.000267%Not Available
Arthritis15.01.01.0010.000392%
Arthropathy15.01.01.0030.000695%Not Available
Asthenia08.01.01.001--Not Available
Blindness06.02.10.003; 17.17.01.0030.000178%Not Available
Blood cholesterol13.12.01.014--Not Available
Blood cholesterol increased13.12.01.002--
Blood pressure increased13.14.03.005--Not Available
Blood prolactin increased13.10.03.002--Not Available
Blood triglycerides13.12.03.004--Not Available
Blood triglycerides increased13.12.03.001--Not Available
Bone disorder15.02.04.004--Not Available
Bruxism07.01.06.008; 19.11.03.0010.001480%Not Available
Burning sensation17.02.06.001; 08.01.09.029--Not Available
Cardiovascular disorder02.11.01.010; 24.03.02.0090.000178%Not Available
Cataract06.06.01.0010.000178%
The 1th Page    1 2 3 4 5    Next   Last    Total 11 Pages